Intramuscular administration of paliperidone palmitate extended-release injectable microsuspension induces a subclinical inflammatory reaction modulating the pharmacokinetics in rats

Journal of Pharmaceutical Sciences

Volumn 103, Issue 7, 2014, Pages 2072-2087

  Darville, Nicolas ^a   Van Heerden, Marjolein ^b   Vynckier, An ^b   De Meulder, Marc ^b   Sterkens, Patrick ^b   Annaert, Pieter ^a   Van Den Mooter, Guy ^a  

^a DEPARTMENT OF PHARMACEUTICAL AND PHARMACOLOGICAL SCIENCES   (Belgium)

^b JANSSEN RESEARCH AND DEVELOPMENT   (Belgium)

Author keywords

biocompatibility; disposition; histopathology; inflammation; muscle; nanoparticles; paliperidone palmitate; pharmacokinetics; prodrugs; sustained release

Indexed keywords

PALIPERIDONE; DELAYED RELEASE FORMULATION; ISOXAZOLE DERIVATIVE; NANOPARTICLE; PALMITIC ACID DERIVATIVE; PRODRUG; SUSPENSION;

ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CELL INFILTRATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG HALF LIFE; DRUG SOLUBILITY; DRUG TISSUE LEVEL; ECHOGRAPHY; EXTENDED RELEASE INJECTABLE MICROSUSPENSION; FLUORESCENCE MICROSCOPY; FOREIGN BODY REACTION; GRANULOMATOUS INFLAMMATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; LASER DIFFRACTION; MACROPHAGE; MALE; MAXIMUM PLASMA CONCENTRATION; MORPHOLOGY; NONHUMAN; PARTICLE SIZE; PHAGOCYTOSIS; POLARIZATION MICROSCOPY; RAT; SCANNING ELECTRON MICROSCOPY; SINGLE DRUG DOSE; SUSPENSION; TIME TO MAXIMUM PLASMA CONCENTRATION; TRANSMISSION ELECTRON MICROSCOPY; X RAY DIFFRACTION; ANIMAL; BIOLOGICAL MODEL; CHEMISTRY; DELAYED RELEASE FORMULATION; INTRAMUSCULAR DRUG ADMINISTRATION; METABOLISM; PATHOLOGY; SKELETAL MUSCLE; SURFACE PROPERTY; TISSUE DISTRIBUTION; WISTAR RAT;

ANIMALS; DELAYED-ACTION PREPARATIONS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INJECTIONS, INTRAMUSCULAR; ISOXAZOLES; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; MODELS, BIOLOGICAL; MUSCLE, SKELETAL; NANOPARTICLES; PALMITATES; PARTICLE SIZE; PRODRUGS; RATS, WISTAR; SURFACE PROPERTIES; SUSPENSIONS; TISSUE DISTRIBUTION;

EID: 84902969006     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24014     Document Type: Article

References (46)

1. Shi Y, Li LC., 2005. Current advances in sustained-release systems for parenteral drug delivery. Expert Opin Drug Deliv 2 (6): 1039-1058. (Pubitemid 41701203)
2. Kipp JE,. 2004. The role of solid nanoparticle technology in the parenteral delivery of poorly water-soluble drugs. Int J Pharm 284 (1-2): 109-122. (Pubitemid 39349144)
3. Van Eerdenbrugh B, Van den Mooter G, Augustijns P,. 2008. Top-down production of drug nanocrystals: Nanosuspension stabilization, miniaturization and transformation into solid products. Int J Pharm 364 (1): 64-75.
4. Baert L, van't Klooster G, Dries W, François M, Wouters A, Basstanie E, Iterbeke K, Stappers F, Stevens P, Schueller L, Van Remoortere P, Kraus G, Wigerinck P, Rosier J,. 2009. Development of a long-acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 72 (3): 502-508.
5. Lindenmayer J,. 2010. Long-acting injectable antipsychotics: Focus on olanzapine pamoate. Neuropsychiatr Dis Treat 6: 261-267.
6. Kramer M, Litman R, Hough D, Lane R, Lim P, Liu Y, Eerdekens M,. 2010. Paliperidone palmitate, a potential long-acting treatment for patients with schizophrenia. Results of a randomized, double-blind, placebo-controlled efficacy and safety study. Int J Neuropsychopharmacol 13 (5): 635-647.
7. Samtani MN, Vermeulen A, Stuyckens K,. 2009. Population pharmacokinetics of intramuscular paliperidone palmitate in patients with schizophrenia: A novel once-monthly, long-acting formulation of an atypical antipsychotic. Clin Pharmacokinet 48 (9): 585-600.
8. Hirano K, Ichihashi T, Yamada H,. 1981. Studies on the absorption of practically water-insoluble drugs following injection. II. Intramuscular absorption from aqueous suspensions in rats. Chem Pharm Bull 29 (3): 817-827. (Pubitemid 11124670)
9. Zuidema J, Kadir F, Titulaer HAC, Oussoren C,. 1994. Release and absorption rates of intramuscularly and subcutaneously injected pharmaceuticals (II). Int J Pharm 105 (3): 189-207. (Pubitemid 24103997)
10. Anderson JM, Niven H, Pelagalli J, Olanoff LS, Jones RD,. 1981. The role of the fibrous capsule in the function of implanted drug-polymer sustained release systems. J Biomed Mater Res 15 (6): 889-902. (Pubitemid 12239964)
11. Medlicott NJ, Waldron NA, Foster TP,. 2004. Sustained release veterinary parenteral products. Adv Drug Deliv Rev 56 (10): 1345-1365. (Pubitemid 38748820)
12. Ballard BE, Nelson E,. 1962. Absorption of implanted solid drug. J Pharm Sci 51 (10): 915-924.
13. van't Klooster G, Hoeben E, Borghys H, Looszova A, Bouche M-P, van Velsen F, Baert L,. 2010. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-acting injectable antiretroviral formulation. Antimicrob Agents Chemother 54 (5): 2042-2050.
14. Hill A, Breyer S, Geissler S, Mier W, Haberkorn U, Weigandt M, Mäder K,. 2013. How do in-vitro release profiles of nanosuspensions from Alzet® pumps correspond to the in-vivo situation? A case study on radiolabeled fenofibrate. J Control Release 168 (1): 77-87.
15. Reynolds ES,. 1963. The use of lead citrate at high pH as an electron-opaque stain in electron microscopy. J Cell Biol 17 (1): 208-212.
16. Hough D, Lindenmayer J-P, Gopal S, Melkote R, Lim P, Herben V, Yuen E, Eerdekens M,. 2009. Safety and tolerability of deltoid and gluteal injections of paliperidone palmitate in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 33 (6): 1022-1031.
17. Raritan N, Janssen Pharmaceutical Research & Development LLC. Clinical study report. Open-label, parallel, randomized, dose proportionality pharmacokinetic study of paliperidone after intramuscular injection of paliperidone palmitate in the deltoid or gluteal muscle in subjects with schizophrenia. Data on file at Janssen Research & Development.
18. Tseng J-C, Kung AL,. 2012. In vivo imaging of inflammatory phagocytes. Chem Biol 19 (9): 1199-1209.
19. Hawley AE, Davis SS, Illum L,. 1995. Targeting of colloids to lymph nodes: Influence of lymphatic physiology and colloidal characteristics. Adv Drug Deliv Rev 17 (1): 129-148.
20. Wu PI, Minisini S, Edelman ER,. 2009. Intramuscular drug transport under mechanical loading: Resonance between tissue function and uptake. J Control Release 136 (2): 99-109.
21. Bjerregaard S, Pedersen H, Vedstesen H, Vermehren C, Söderberg I, Frokjaer S,. 2001. Parenteral water/oil emulsions containing hydrophilic compounds with enhanced in vivo retention: Formulation, rheological characterisation and study of in vivo fate using whole body gamma-scintigraphy. Int J Pharm 215 (1-2): 13-27. (Pubitemid 32206600)
22. Moghimi SM, Hunter AC,. 2000. Poloxamers and poloxamines in nanoparticle engineering and experimental medicine. Trends Biotechnol 18 (10): 412-420.
23. Robbins SL, Kumar V, Cotran RS,. 2010. Robbins and cotran pathologic basis of disease. Philadelphia, Pennsylvania: Saunders/Elsevier, pp 43-77.
24. Zuidema J, Pieters FAJM, Duchateau GSMJE,. 1988. Release and absorption rate aspects of intramuscularly injected pharmaceuticals. Int J Pharm 47 (1-3): 1-12.
25. Laine PS, Schwartz EA, Wang Y, Zhang W-Y, Karnik SK, Musi N, Reaven PD,. 2007. Palmitic acid induces IP-10 expression in human macrophages via NF-kappaB activation. Biochem Biophys Res Commun 358 (1): 150-155. (Pubitemid 46719095)
26. Ajuwon KM, Spurlock ME,. 2005. Palmitate activates the NF-kappaB transcription factor and induces IL-6 and TNFalpha expression in 3T3-L1 adipocytes. J Nutr 135 (8): 1841-1846. (Pubitemid 41099739)
27. Anderson FD, Archer DF, Harman SM, Leonard RJ, Wilborn WH,. 1993. Tissue response to bioerodible, subcutaneous drug implants: A possible determinant of drug absorption kinetics. Pharm Res 10 (3): 369-380. (Pubitemid 23080600)
28. Ahsan F, Rivas IP, Khan MA, Torres Suárez AI,. 2002. Targeting to macrophages: Role of physicochemical properties of particulate carriers-liposomes and microspheres-on the phagocytosis by macrophages. J Control Release 79 (1-3): 29-40. (Pubitemid 34164159)
29. Champion JA, Walker A, Mitragotri S,. 2008. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res 25 (8): 1815-1821.
30. Lunov O, Syrovets T, Loos C, Beil J, Delacher M, Tron K, Nienhaus GU, Musyanovych A, Mailänder V, Landfester K, Simmet T,. 2011. Differential uptake of functionalized polystyrene nanoparticles by human macrophages and a monocytic cell line. ACS Nano 5 (3): 1657-1669.
31. Nel AE, Mädler L, Velegol D, Xia T, Hoek EMV, Somasundaran P, Klaessig F, Castranova V, Thompson M,. 2009. Understanding biophysicochemical interactions at the nano-bio interface. Nat Mater 8 (7): 543-557.
32. Yue H, Wei W, Yue Z, Lv P, Wang L, Ma G, Su Z,. 2010. Particle size affects the cellular response in macrophages. Eur J Pharm Sci 41 (5): 650-657.
33. Hillaireau H, Couvreur P,. 2009. Nanocarriers' entry into the cell: Relevance to drug delivery. Cell Mol Life Sci 66 (17): 2873-2896.
34. Tabata Y, Ikada Y,. 1988. Effect of the size and surface charge of polymer microspheres on their phagocytosis by macrophage. Biomaterials 9 (4): 356-362.
35. Owens DE 3rd, Peppas NA,. 2006. Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles. Int J Pharm 307 (1): 93-102. (Pubitemid 41773257)
36. Daugherty AL, Cleland JL, Duenas EM, Mrsny RJ,. 1997. Pharmacological modulation of the tissue response to implanted polylactic-co-glycolic acid microspheres. Eur J Pharm Biopharm 44 (1): 89-102. (Pubitemid 28298779)
37. Rabinow BE,. 2004. Nanosuspensions in drug delivery. Nat Rev Drug Discov 3 (9): 785-796. (Pubitemid 39242830)
38. Annaert P, Steemans K, Mannens G, Mamidi R, Boom S, Sterkens P,. 2005. In vitro study on transepithelial transport of the psychotropic compound paliperidone (PAL) across Caco-2 monolayers. Drug Metab Rev 37 (Suppl 1): 15.
39. Satoh T, Hemmerlein B, Zschunke F, Radzun HJ,. 1999. In situ detection of human monocyte/macrophage serine esterase-1 mRNA expression in human tissues. Pathobiology 67 (3): 158-162. (Pubitemid 29304377)
40. Satoh T, Taylor P, Bosron WF, Sanghani SP, Hosokawa M, Du BNL,. 2002. Current progress on esterases: From molecular structure to function. Drug Metab Dispos 30 (5): 488-493. (Pubitemid 34456967)
41. Van Manen H-J, van Apeldoorn AA, Verrijk R, van Blitterswijk CA, Otto C,. 2007. Intracellular degradation of microspheres based on cross-linked dextran hydrogels or amphiphilic block copolymers: A comparative Raman microscopy study. Int J Nanomed 2 (2): 241-252. (Pubitemid 47215025)
42. Lietz CB, Gemperline E, Li L,. 2013. Qualitative and quantitative mass spectrometry imaging of drugs and metabolites. Adv Drug Deliv Rev 65 (8): 1074-1085.
43. Chang DT, Jones JA, Meyerson H, Colton E, Kwon IK, Matsuda T, Anderson JM,. 2008. Lymphocyte/macrophage interactions: Biomaterial surface-dependent cytokine, chemokine, and matrix protein production. J Biomed Mater Res A 87 (3): 676-687.
44. Baik J, Rosania GR,. 2012. Macrophages sequester clofazimine in an intracellular liquid crystal-like supramolecular organization. PloS One 7 (10): e47494.
45. Bhardwaj U, Burgess DJ,. 2010. A novel USP apparatus 4 based release testing method for dispersed systems. Int J Pharm 388 (1-2): 287-294.
46. Johnson KC,. 2012. Comparison of methods for predicting dissolution and the theoretical implications of particle-size-dependent solubility. J Pharm Sci 101 (2): 681-689.